Key Insights

Highlights

Treatment Research

5 treatments under study, led by Mrg 003

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 1/2 (1)
Phase 2 (1)

Trial Status

Recruiting2
Unknown1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07464366Phase 2RecruitingPrimary

The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study

NCT03556228Phase 1/2Recruiting

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

NCT05013515Not ApplicableUnknownPrimary

Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas

Showing all 3 trials

Research Network

Common Treatments

  • Mrg 0031
  • Pucotenlimab1
  • Surufatinib1
  • Vmd928 Tablet And Pembrolizumab 200 Mg1
  • Vmd928 100 Mg Tablet1

Active Sponsors

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University1
  • VM Oncology, LLC1
  • Ji Dongmei1

Top Investigators

  • Min Ruan, MD1

    Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Related Conditions

  • Head And Neck Carcinoma1
  • Head And Neck Cancers Throat1
  • Head And Neck Squamous Cell Carcinoma1
  • Nonsmall Cell Lung Cancer1
  • Small Cell Lung Cancer Sclc1

Activity Timeline